<- Go Home
Vical Incorporated
As of August 31, 2019, Vical Incorporated was acquired by Brickell Biotech, Inc., in a reverse merger transaction. Vical Incorporated researches and develops biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company was founded in 1987 and is headquartered in San Diego, California.
Market Cap
$15.3M
Volume
26.2K
Cash and Equivalents
$10.8M
EBITDA
-$13.3M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$6.8M
Profit Margin
4000.00%
52 Week High
$10.29
52 Week Low
$4.20
Dividend
N/A
Price / Book Value
0.37
Price / Earnings
-1.22
Price / Tangible Book Value
0.37
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-$13.3M
Return on Equity
25.49%
Return on Assets
-16.73
Cash and Short Term Investments
$41.7M
Debt
N/A
Equity
$41.5M
Revenue
$171.0K
Unlevered FCF
-$9.3M
Sector
Biotechnology
Category
N/A